CRESTONE, INC. - TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES.

PIID: 75N93020C00020Solicitation ID: HHS-NIH-NIAID-BAA2019-1

Signed Date: Jun 29, 2020Effective Date: Jul 1, 2020End Date: Closes in 141 days

Award $

$22.0M

Vendor

CRESTONE, INC.

NAICS

541715

Signed Date

Jun 29, 2020

Key Details

Dollars Obligated

$22.0M

Base & All Options

$27.0M

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

BOULDER, CO

TO ADVANCE A PROMISING, SMALL-MOLECULE COMPOUND CRS0540 TO IND FILING AND THROUGH PHASE I CLINICAL STUDIES.

On Jun 29, 2020, Department of Health and Human Services obligated $22,028,937 to CRESTONE, INC. for to advance a promising, small-molecule compound crs0540 to ind filing and through phase i clinical studies.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Competition extent: full and open competition with 12 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BOULDER, CO. The contract is scheduled through Jan 31, 2027 — approximately 5 months remaining.